- $116.26m
- $145.26m
- $94.64m
Societal CDMO Inc reports results for the quarter ended in March - Earnings Summary
Brief: Societal CDMO Reports First Quarter 2022 Financial Results
Societal CDMO Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With Infectopharm For Ritalin La® In Europe
Societal CDMO Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Societal CDMO Secures Manufacturing And Packaging Task Order Award From National Cancer Institute
Brief: Recro Pharma Inc Announces That It Is Changing Its Name To Societal Cdmo Inc
Recro Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Recro Reports Fourth Quarter And Year End 2021 Financial Results
Recro Pharma Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Recro Pharma Inc -
Recro Pharma Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Recro Wins $1.5 Mln Contract To Support Clinical Development Of Topical Treatment For Skin Cancer Prevention
Recro Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Recro Pharma Reports Q3 Loss Per Share $0.07
Brief: Recro Pharma Awarded Development And Manufacturing Contract By National Institutes Of Health (Nih) To Support Novel Nasal Spray Analgesic
Brief: Recro Signs Renewable Energy Agreement With Georgia Power
Brief: Recro Pharma Inc Files Prospectus Relates To Resale Of Up To 9.3 Million Shares
Brief: Recro And Biocorrx Expand Development And Manufacturing Relationship To Support Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder